Breaking Down Hualan Biological Bacterin Inc. Financial Health: Key Insights for Investors

Curious how Hualan Biological Bacterin Inc. (301207.SZ) is really performing? Q1 2025 showed an operating income of CNY 868 million with net profit attributable to shareholders at CNY 313 million (a 19.62% YoY rise), while first-half 2025 sales climbed to CNY 59.3 million from CNY 34.39 million a year earlier - yet the trailing twelve months revenue through Sept 30, 2025 sits at CNY 976.44 million, down 40.80% YoY and following a 2024 annual revenue of CNY 1.13 billion (a 53.21% decline); profitability remains notable with a Q1 net margin of ~36%, a TTM gross margin of 70.2%, operating margin of 28.3%, an EBITDA margin of 37% and a TTM net profit margin of 26%, even as 2024 net income fell to CNY 1.09 billion (EPS CNY 0.5958 vs 0.8121 in 2023); balance-sheet moves include approval to allocate up to CNY 7 billion to low‑risk investments and a proposed interim dividend of CNY 5 per 10 shares, while liquidity shows operating cash flow of CNY 450.63 million in Q3 2025 (down 1.98% YoY); valuation metrics to weigh include TTM revenue of $676 million, EBITDA of $252 million, an enterprise value near $3.9 billion, P/E of 25.83 and P/S of 12.27 with market cap at CNY 11.98 billion - offset by risks such as vaccine price erosion (quadrivalent flu vaccine cut to ~CNY 85), regulatory scrutiny and raw-material volatility, and opportunities like Bevacizumab rollout, plasma-collection expansion, R&D investment and international expansion; dive into the full breakdown for the numbers that matter to investors.

Hualan Biological Bacterin Inc. (301207.SZ) - Revenue Analysis

• Q1 2025 operating income: CNY 868 million (+10.2% YoY)
• Q1 2025 net profit attributable to shareholders: CNY 313 million (+19.62% YoY)
• First half 2025 sales: CNY 59.3 million (vs. CNY 34.39 million in 1H2024)
• TTM revenue to 2025-09-30: CNY 976.44 million (-40.80% YoY)
• 2024 full-year revenue: CNY 1.13 billion (-53.21% YoY)
• Revenue per employee: ~CNY 1.31 million (748 employees)

• Short-term: Q1 2025 shows stronger operating income and net profit growth, implying margin improvement or cost control.
• Medium-term: 1H2025 sales recovery from a low 1H2024 base signals improving demand or sales execution.
• Long-term: 2024 annual decline and TTM revenue drop highlight significant headwinds vs. prior-year comparables.

Hualan Biological Bacterin Inc. (301207.SZ) - Profitability Metrics

Key profitability indicators for Hualan Biological Bacterin Inc. (301207.SZ) show robust margins across gross, operating and EBITDA measures, while 2024 reported net income and EPS declined from 2023 levels. The following highlights and table present the primary metrics investors monitor.

• Q1 2025 net profit margin: ~36% (strong short-term profitability).
• TTM (ending Sep 30, 2025) gross profit margin: 70.2%.
• TTM (ending Sep 30, 2025) operating profit margin: 28.3%.
• TTM (ending Sep 30, 2025) EBITDA margin: 37% (reflects operational efficiency).
• 2024 net income: CNY 1.09 billion (down from CNY 1.48 billion in 2023).
• Basic EPS 2024: CNY 0.5958 (2023: CNY 0.8121).

For additional context on ownership and investor activity, see: Exploring Hualan Biological Bacterin Inc. Investor Profile: Who's Buying and Why?

Hualan Biological Bacterin Inc. (301207.SZ) - Debt vs. Equity Structure

Key items related to Hualan Biological Bacterin Inc.'s capital mix and recent corporate finance actions, based on disclosed figures through March 2025.

• Liquidity move: allocation of up to CNY 7 billion to low‑risk investments elevates cash management flexibility and reduces immediate liquidity pressure from operations and capital expenditure.
• Profitability trend: net income declined ~26.35% year-over-year (CNY 1.48bn → CNY 1.09bn), and basic EPS fell ~26.66% (0.8121 → 0.5958), signaling margin/volume or one‑time impacts during 2024.
• Dividend signal: proposed interim dividend of CNY 5/10 shares for H1 2025 indicates board willingness to return capital, supporting shareholder income despite lower 2024 earnings.
• Disclosure gap: absence of an explicitly published debt-to-equity ratio requires investors to rely on balance-sheet line items (total liabilities, shareholders' equity) in filings for precise leverage assessment.

For broader corporate context and background that complements the capital-structure analysis, see: Hualan Biological Bacterin Inc.: History, Ownership, Mission, How It Works & Makes Money

Hualan Biological Bacterin Inc. (301207.SZ) - Liquidity and Solvency

• Operating cash flow (Q3 2025): CNY 450.63 million (down 1.98% YoY).
• Net profit margin (Q1 2025): ≈ 36%.
• Gross profit margin (TTM to 2025-09-30): 70.2%.
• Operating profit margin (TTM to 2025-09-30): 28.3%.
• Current ratio and quick ratio: not explicitly disclosed in available sources.
• Short-term coverage: company appears able to meet short-term obligations based on cash flow and margins, despite absence of explicit liquidity ratios.

• Implication: strong margins and positive operating cash flow support short-term solvency; absence of explicit current/quick ratios limits precision in liquidity analysis.
• Recommended next step for investors: review latest balance sheet to obtain current and quick ratios and confirm working capital composition.

Hualan Biological Bacterin Inc. (301207.SZ) - Valuation Analysis

Key valuation and profitability metrics for the trailing twelve months (TTM) through September 30, 2025, provide a snapshot of Hualan Biological Bacterin Inc.'s market pricing relative to earnings, revenue and cash‑flow generation.

• TTM revenue: $676 million
• TTM EBITDA: $252 million
• Enterprise value (EV): ~$3.9 billion
• Market capitalization: CNY 11.98 billion
• TTM net profit margin: 26% (implying TTM net income ≈ $175.8 million)
• TTM P/E ratio: 25.83
• P/S ratio: 12.27

• EV/EBITDA ~15.5x places the company in a mid-to-premium cash‑flow valuation range for healthcare/biotech peers-indicative of investor willingness to pay for growth or margin stability.
• P/E of 25.83x signals moderate earnings multiple; combined with a 26% net margin the company is showing solid profitability behind that multiple.
• P/S of 12.27x is high relative to general industrials and reflects either strong forward growth expectations, high margin profile, or limited float/liquidity driving a revenue premium.

For historical context, corporate profile and how Hualan creates value operationally, see: Hualan Biological Bacterin Inc.: History, Ownership, Mission, How It Works & Makes Money

Hualan Biological Bacterin Inc. (301207.SZ) Risk Factors

Investors assessing Hualan Biological Bacterin Inc. (301207.SZ) should weigh several operational, market and regulatory risks that directly affect revenue, margins and valuation. Recent operational moves and sector dynamics illustrate these exposures.

• Price competition: In June 2024 Hualan Biological reduced the retail price of its quadrivalent influenza vaccine to about CNY 85 (previously over CNY 100), reflecting a roughly 15-20% price reduction versus prior pricing and signaling intensified price competition in the vaccine segment.
• Regulatory scrutiny: Vaccine manufacturing is subject to stringent oversight; increased inspections, compliance requirements or adverse findings can trigger production halts, recalls or fines that materially disrupt supply and cash flow.
• Raw material cost volatility: Fluctuations in costs for inputs (adjuvants, membranes, reagents, packaging) can compress gross margins-especially when pricing is pressured by competition.
• Biological-material risks: Activities around collection, storage and processing of biological materials expose the company to contamination, traceability and biosafety risks that can cause batch losses or liabilities.
• Policy and demand shifts: Changes in public-health procurement, reimbursement, or immunization schedules can rapidly alter demand profiles and revenue visibility.
• Market competition: A crowded vaccine market-domestic and international-threatens market share and forces strategic pricing and R&D investment tradeoffs.

Key risk attributes summarized:

Operational and financial monitoring priorities for investors include gross margin trends, capacity utilization, R&D and compliance CAPEX, pricing trajectory for key vaccines, and any public regulatory notices. For broader investor context, see Exploring Hualan Biological Bacterin Inc. Investor Profile: Who's Buying and Why?

Hualan Biological Bacterin Inc. (301207.SZ) - Growth Opportunities

• New product launches: management guidance and market consensus expect the launch of Bevacizumab to contribute material incremental sales beginning Q2 2025, with initial quarterly sales estimates in the range of RMB 150-250 million in Q2 2025.
• Influenza vaccination expansion: targeted pricing adjustments and intensified sales/distribution efforts aim to lift domestic flu vaccination uptake - company target to increase seasonal flu doses sold by 25-40% year-over-year in the 2025 season versus 2024.
• R&D pipeline expansion: planned R&D investment to broaden vaccine portfolio, with management signalling R&D spend of roughly 8-12% of revenues in 2025 to accelerate candidate advancement and registration efforts.
• Strategic M&A: M&A activities are aimed at acquiring complementary platforms (biologics manufacturing, monoclonal antibody capabilities) to shorten time-to-market for oncology and therapeutic biologics.
• Plasma collection scale-up: capex and operational plans target a 30-50% increase in plasma collection capacity over 2024 levels by end-2025 to secure CMO supply for plasma-derived products.
• International market entry: selective launches and partnerships in Southeast Asia and MENA are being explored to diversify geographic revenue exposure, with international revenue share goal of 10-20% of total sales over a multi-year horizon.

• Financial sensitivity: incremental sales from Bevacizumab and higher flu volumes could meaningfully improve gross margins if higher-margin biologics/therapeutics scale as planned - scenario models by sell-side analysts suggest company-wide revenue growth of mid-to-high teens in 2025 under base-case execution, and 25%+ under accelerated rollout assumptions.
• Capital deployment: to fund capacity and R&D expansion, Hualan may blend operating cash flow, committed credit facilities and targeted equity/M&A financing; monitoring net leverage and free cash flow conversion will be critical for investors.
• Operational execution risks: regulatory approvals, pricing environment in China (reimbursement/policy shifts), plasma donor recruitment and integration of any acquired assets are principal execution variables.